Discovery

 

MVI is developing Simple, Safe, Effective and Economical immune-activating therapies for men with all stages of prostate cancer.

“Although commonly referred to as ‘vaccines,’ our products are actually forms of gene-based immunotherapy. They are taken up by cells to stimulate specific responses using the body’s natural mechanisms to fight the cancer.”

Richard R. Lesniewski, PhD

MVI President and CEO

BENEFITS

 

Simple Manufacturing

 

Combined Cost Of Goods for our immune-activating agents portend favorable reimbursement potential for use in combination with checkpoint inhibitors or with androgen deprivation therapies

 

Our product candidates are in clinical trials as monotherapy, and as combination therapy with approved agents.

 

MVI products are readily manufactured, highly stable, and are administered by simple skin injection. We target patients with the highest risk of developing bone or other metastases after their initial therapy as well as patients who have already developed metastatic prostate cancer.

 

“Our immune-activators do not have to be tailored to each individual patient, and unlike other investigational vaccines, ours can be delivered by simple injections into the skin.”

Technology

 

Our immune-activating therapies use plasmid DNA (genetically engineered material encoding a human antigen) to develop immunotherapies that activate the body’s own immune system to target specific features of prostate cancer cells.

 

 

CLINICAL TRIALS

 

MVI is working with premier prostate cancer treatment institutions in the U.S. to insure high quality trials, maximizing its opportunity to achieve safe, effective, approvable, and reimbursable therapies for patients.

BENEFITS

 

Simple Manufacturing

 

Combined Cost Of Goods for our immune-activating agents portend favorable reimbursement potential for use in combination with checkpoint inhibitors or with androgen deprivation therapies

 

Our product candidates are in clinical trials as monotherapy, and as combination therapy with approved agents.

 

MVI products are readily manufactured, highly stable, and are administered by simple skin injection. We target patients with the highest risk of developing bone or other metastases after their initial therapy as well as patients who have already developed metastatic prostate cancer.

 

CLINICAL TRIALS

 

MVI is working with premier prostate cancer treatment institutions in the U.S. to insure high quality trials, maximizing its opportunity to achieve safe, effective, approvable, and reimbursable therapies for patients.

Technology

 

Our immune-activating therapies use plasmid DNA (genetically engineered material encoding a human antigen) to develop immunotherapies that activate the body’s own immune system to target specific features of prostate cancer cells.